Leerink Swann Reaffirms Outperform Rating on Seattle Genetics (SGEN)
SGEN has been the subject of a number of other recent research reports. Analysts at Needham & Company reiterated a “buy” rating on shares of Seattle Genetics in a research note to investors on Tuesday, February 14th. Analysts at Canaccord Genuity reiterated a “sell” rating on shares of Seattle Genetics in a research note to investors on Friday, February 10th.
Shares of Seattle Genetics opened at 18.77 on Wednesday. Seattle Genetics has a 52 week low of $12.29 and a 52 week high of $22.40. The company’s market cap is $2.184 billion.
Seattle Genetics last announced its earnings results on Tuesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). The company’s revenue for the quarter was up 296.5% on a year-over-year basis. On average, analysts predict that Seattle Genetics will post $-0.10 earnings per share next quarter.
Seattle Genetics, Inc. (Seattle Genetics) is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.